Human Chorionic Gonadotropin

hCG is a placental glycoprotein that the body reads as a long-acting luteinizing hormone (LH). Structurally it shares the same α-subunit as LH, FSH, and TSH, but its β-subunit carries an extended C-terminal peptide studded with sialic-acid-rich O-linked glycans — the reason a single injection keeps working for days while native LH is cleared in hours. For individuals using AAS, that glycan tail is the whole point: it lets you rescue the one piece of endocrine machinery that exogenous testosterone shuts off.

LHCGR Agonism and the Steroidogenic Cascade#

hCG binds the LH/choriogonadotropin receptor (LHCGR) on testicular Leydig cells — a Gs-coupled GPCR. Activation drives adenylate cyclase → cAMP → PKA, which phosphorylates and upregulates the StAR protein (the rate-limiting step moving cholesterol into the mitochondrial inner membrane) and induces the full steroidogenic enzyme cascade: P450scc, 3β-HSD, 17α-hydroxylase, 17,20-lyase, and 17β-HSD. The end product is testosterone, synthesized locally inside the testicle.

"hCG acts as a high-potency, long-lasting LH receptor agonist, driving the full steroidogenic cascade in Leydig cells, including upregulation of StAR protein and testosterone biosynthesis." — Casarini L. et al., Endocrine Reviews, 2018

Practically: when the hypothalamus stops sending GnRH because serum T is supraphysiologic on cycle, the testes stop making testosterone and shrink. hCG bypasses the hypothalamus and pituitary entirely and flips Leydig cells back on at the receptor level. That's why it works on-cycle when a SERM would be useless — there's no pituitary drive left to salvage.

Restoring Intratesticular Testosterone (ITT)#

Serum testosterone and intratesticular testosterone are two different pools. ITT runs ~50–100× higher than serum T in a healthy male and is required for spermatogenesis and for maintaining testicular volume. Exogenous testosterone — even at 500 mg/week cruising supraphysiologic serum levels — collapses ITT because LH is suppressed and the Leydig cells go quiet. This is the mechanism behind testicular atrophy and the fertility hit from long cycles.

Low-dose hCG rescues this pool without needing much drug:

"Only low-dose hCG (125–500 IU EOD) maintained intratesticular testosterone concentrations within the normal range in the setting of exogenous T-induced suppression." — Coviello AD. et al., Journal of Clinical Endocrinology & Metabolism, 2005

This single trial is the mechanistic backbone of the 250 IU SC twice weekly community protocol. You don't need more, and more is actively counterproductive (see Leydig desensitization below). If your goal is keeping fullness in the sack and preserving fertility optionality across a long blast-and-cruise, this is the receptor-level reason the dose is so small.

Leydig-Cell Aromatase and the Estrogen Problem#

LHCGR activation doesn't only turn on testosterone synthesis — it also upregulates Leydig-cell aromatase (CYP19A1). So a meaningful fraction of hCG-driven testosterone is aromatized to estradiol inside the testicle before it even reaches systemic circulation. Per unit testosterone produced, hCG generates noticeably more E2 than exogenous test esters do.

Translation for the user: in cycles that already push estrogen, adding hCG will tilt the E2:T ratio further upward. This is why gyno flares, water retention, and mood swings often appear when someone adds hCG rather than when they start the cycle. Keep an AI on hand (anastrozole 0.25–0.5 mg E3D is usually enough at 250 IU 2×/week) and pull bloodwork 4–6 weeks after introducing hCG.

Dose-Dependent Leydig Desensitization#

Chronic high-dose hCG does the opposite of what you want. Sustained LHCGR occupancy downregulates the receptor and selectively impairs 17,20-lyase activity — the enzyme that converts 17-hydroxyprogesterone into androstenedione on the way to testosterone. The result is a paradoxical buildup of 17-OHP and progesterone with a blunted testosterone response over time.

"High and sustained hCG dosing caused progressive elevation of 17-hydroxyprogesterone and a paradoxical decrease in androgen response, suggesting Leydig-cell desensitization and impaired 17,20-lyase activity." — Forest MG. et al., Journal of Clinical Endocrinology & Metabolism, 1979

This is why the old-school "5,000 IU twice a week" protocols have fallen out of favor and why PCT kickstart doses are capped at 1,500–2,500 IU EOD for 2–3 weeks, not indefinitely. Push past that window and you're actively making the restart harder — blunted androgen output, inflated progesterone and estradiol, and a hypothalamus that sees enough E2 to stay suppressed even after the SERM kicks in.

Pharmacokinetics That Drive the Dosing Schedule#

hCG clearance is biphasic: an initial distribution phase around 6 hours and a terminal elimination half-life of ~33 hours. Serum hCG peaks at ~6 h after IM and ~16–24 h after SC, but the testosterone response lags — peak T occurs 48–96 h post-injection. That's why EOD or twice-weekly schedules work cleanly: you're dosing on the trailing edge of the previous T peak.

Subcutaneous administration gives essentially complete bioavailability versus IM, with a flatter, more prolonged curve:

"After subcutaneous injection, hCG was absorbed nearly completely with a delayed but prolonged peak concentration compared to intramuscular administration. Both routes showed clinically equivalent pharmacodynamic and testosterone responses." — Saal W. et al., Fertility and Sterility, 1991

For the user this means an insulin syringe into the lower belly is both more comfortable and more accurate at small doses than a 25g IM pin — and the testosterone endpoint is the same. SC is the default route for anyone running 250–500 IU at a time, which is effectively everyone on a maintenance protocol.

Common (most users)#

• Estrogen rise (water retention, nipple sensitivity, moodiness, slight fat gain) — the #1 real-world issue. Leydig-cell aromatase is cranked harder per unit T than on exogenous test, so E2 often runs high relative to total T. Drop the hCG dose first (250 IU 2×/week is the sweet spot), add anastrozole 0.25–0.5 mg E3D only if symptoms persist. Don't reflexively crush E2 — check sensitive E2 on bloods first.
• Testicular fullness / mild aching — expected, especially in the first week or two after restarting hCG on a cruise. Means it's working. No action needed unless pain is sharp or persistent.
• Acne, oily skin, libido swings — downstream of the T/E2 swings themselves. Usually settles once you dial in a steady twice-weekly cadence instead of big spaced-out boluses.
• Injection-site bump or redness — negligible with SC insulin-syringe administration into the lower abdomen or thigh. Rotate sites and let reconstituted vials come to room temp before pinning.
• Headache, mild fatigue, transient edema — almost always dose-related. Resolves at the 250 IU level. If it doesn't, check E2.

Uncommon (dose-dependent or individual)#

• Leydig-cell desensitization — sustained dosing at ≥1,500 IU multiple times per week downregulates the LH receptor and impairs 17,20-lyase, producing rising 17-OHP/progesterone and a blunting androgen response over time. This is why the old-school "5,000 IU 2×/week forever" protocols fell out of favor.

"High and sustained hCG dosing caused progressive elevation of 17-hydroxyprogesterone and a paradoxical decrease in androgen response, suggesting Leydig-cell desensitization and impaired 17,20-lyase activity." — Forest MG, Lecoq A, Saez JM. J Clin Endocrinol Metab (1979).

Back off to maintenance dose. The Coviello data is unambiguous that 250–500 IU EOD is all that's needed to hold ITT.

"Only low-dose hCG (125–500 IU EOD) maintained intratesticular testosterone concentrations within the normal range in the setting of exogenous T-induced suppression." — Coviello AD et al., JCEM (2005).

• Gynecomastia — the susceptible subset who gyno'd on prior cycles will gyno faster on hCG if E2 isn't watched. Pull bloods 4–6 weeks into any new hCG protocol (sensitive E2 + total T + SHBG). Raloxifene 60 mg/day salvages early tissue; don't wait on it.
• Prolonged HPTA suppression from solo use — running hCG alone at the tail of a cycle without a SERM can deepen and extend shutdown via estrogen negative feedback on the hypothalamus. Always pair PCT-dose hCG with tamoxifen or enclomiphene.
• Elevated hematocrit — indirect, via T elevation on TRT+hCG stacks. Check CBC quarterly; donate blood if HCT creeps past ~52%.
• Pregnancy-test positive / doping-test positive — hCG is detectable for 7–10+ days and is banned by WADA/USADA in males. If you're drug-tested, this compound is not for you.

Rare but serious#

• Thromboembolism — almost all reports come from the ART / ovarian-hyperstimulation context in women, not male dosing, but the mechanism (estrogen-driven hypercoagulability) applies. Warning signs: unilateral calf swelling, pleuritic chest pain, sudden severe headache with visual changes. Stop and get worked up immediately.
• Hypersensitivity / anaphylaxis — rare, mainly associated with urinary-derived preparations (Pregnyl, Novarel) rather than recombinant (Ovidrel). Switch to recombinant if you develop urticaria, wheeze, or swelling.
• Accelerated growth of an occult androgen-sensitive tumor — hCG drives testosterone, and testosterone feeds prostate cancer and some breast cancers. Baseline PSA before starting chronic hCG in men over 40 is not optional.

Hard contraindications#

• Prostate carcinoma or any known androgen-sensitive malignancy — absolute. hCG drives the full steroidogenic cascade and will feed the tumor.
• hCG monotherapy as PCT off a real cycle — does not restart the hypothalamus or pituitary, only the testes. Will prolong shutdown. Always pair with a SERM (tamoxifen 20 mg/day or enclomiphene 12.5–25 mg/day).

"A typical regimen for post–anabolic steroid recovery consists of hCG at doses of 1,500 to 3,000 IU administered EOD for two to three weeks, followed by a SERM such as tamoxifen or clomiphene." — Rahnema CD et al., Fertility and Sterility (2014).

• Prior hypersensitivity to hCG or urinary gonadotropin preparations.
• Precocious puberty (adolescents) — not a recreational-user concern but worth stating plainly.
• Drug-tested competitive sport — hCG is explicitly banned in male athletes and detectable 7–10+ days post-injection. No workaround.

Gender and PCT notes#

This profile is male-focused — testicular maintenance, HPTA recovery, fertility restoration. Female dosing for ovulation induction is a completely different clinical use at different doses and is out of scope here.

On PCT specifically: the clean protocol is 1,000–2,500 IU SC EOD for 10–20 days beginning once long esters have cleared (~2 weeks after last test-E/C pin, 3+ weeks for NPP/deca, 4+ for test-U), overlapping day 1 with a SERM that runs 4–6 weeks past the hCG. Keep anastrozole 0.25 mg on hand — the E2 bump from a PCT-dose hCG blast can stall restart if ignored, and a SERM doesn't fix aromatization. Recheck LH/FSH/total T at 6 and 12 weeks post to confirm the HPTA has actually come back rather than assuming it did.